40 North Management Has Trimmed Cadence Design System (CDNS) Holding By $93.15 Million; Intellipharmaceutics Internation (IPCI) Shorts Raised By 16.28%

November 14, 2017 - By Marie Mckinney

Intellipharmaceutics Internation (NASDAQ:IPCI) had an increase of 16.28% in short interest. IPCI’s SI was 1.46M shares in November as released by FINRA. Its up 16.28% from 1.26M shares previously. With 194,100 avg volume, 8 days are for Intellipharmaceutics Internation (NASDAQ:IPCI)’s short sellers to cover IPCI’s short positions. The SI to Intellipharmaceutics Internation’s float is 6.01%. The stock decreased 1.14% or $0.011 on November 14, reaching $0.91. About 113,211 shares traded. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has risen 16.57% since November 14, 2016 and is uptrending. It has underperformed by 0.13% the S&P500.

40 North Management Llc decreased Cadence Design System Inc (CDNS) stake by 38.36% reported in 2017Q2 SEC filing. 40 North Management Llc sold 2.82M shares as Cadence Design System Inc (CDNS)’s stock rose 8.54%. The 40 North Management Llc holds 4.54 million shares with $151.93M value, down from 7.36M last quarter. Cadence Design System Inc now has $12.64 billion valuation. The stock declined 0.48% or $0.21 reaching $44.56 per share. About 2.56M shares traded or 30.61% up from the average. Cadence Design Systems Inc (NASDAQ:CDNS) has risen 37.90% since November 14, 2016 and is uptrending. It has outperformed by 21.20% the S&P500.

Intellipharmaceutics International Inc is a Canada pharmaceutical firm engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has market cap of $31.12 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular.

Analysts await Cadence Design Systems Inc (NASDAQ:CDNS) to report earnings on February, 7. They expect $0.27 earnings per share, up 92.86% or $0.13 from last year’s $0.14 per share. CDNS’s profit will be $76.59M for 41.26 P/E if the $0.27 EPS becomes a reality. After $0.29 actual earnings per share reported by Cadence Design Systems Inc for the previous quarter, Wall Street now forecasts -6.90% negative EPS growth.

Among 9 analysts covering Cadence Design Systems Inc (NASDAQ:CDNS), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. Cadence Design Systems Inc had 23 analyst reports since July 29, 2015 according to SRatingsIntel. The company was initiated on Thursday, October 8 by Benchmark. The stock of Cadence Design Systems Inc (NASDAQ:CDNS) earned “Neutral” rating by DA Davidson on Wednesday, April 6. DA Davidson upgraded the stock to “Buy” rating in Monday, October 10 report. RBC Capital Markets maintained Cadence Design Systems Inc (NASDAQ:CDNS) on Thursday, August 31 with “Buy” rating. Northland Capital maintained it with “Outperform” rating and $25 target in Tuesday, October 27 report. The rating was maintained by RBC Capital Markets on Friday, May 26 with “Buy”. Needham maintained the stock with “Hold” rating in Thursday, September 14 report. The company was initiated on Wednesday, October 19 by Credit Suisse. The rating was maintained by RBC Capital Markets on Thursday, February 9 with “Outperform”. The rating was initiated by RBC Capital Markets on Monday, June 6 with “Outperform”.

Since May 15, 2017, it had 0 insider purchases, and 5 sales for $9.30 million activity. 39,986 Cadence Design Systems Inc (NASDAQ:CDNS) shares with value of $1.40 million were sold by RIBAR GEOFFREY G. 55,000 shares were sold by Cowie James J, worth $1.83M on Monday, May 22. The insider SHOVEN JOHN B sold 50,000 shares worth $1.70 million. 100,000 shares were sold by TAN LIP BU, worth $3.31M on Monday, May 15. ZAMAN ANEEL sold $959,087 worth of stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com